TEL AVIV, Israel, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, today announced that it will report its results for the fourth quarter and fiscal year ended December 31, 2014 before the market open on Tuesday, February 17, 2015.
About Bio Blast Pharma Ltd.
Bio Blast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The Bio Blast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. Bio Blast was founded in 2012 and is traded on the NASDAQ under the symbol "ORPN." For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contact: Michael Rice Founding Partner LifeSci Advisors, LLC email@example.com (646) 597-6979Source: BioBlast Pharma